DUBLIN/PRNewswire/ --

The "Cancer Immunotherapy Market" report has been added to ResearchAndMarkets.com'soffering.

The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% across the globe. Moreover, the market is expected to garner USD 86,678.7 Million by the end of 2027.

The global demand for Cancer Immunotherapy is increasing due to massive growth of healthcare industry across the globe. Further, increasing awareness about early diagnosis and advanced personalized medicine as a part of targeted therapy is key growth driver for global Cancer Immunotherapy market over the forecast period.

North America is slated to account for a share of 37.0% by 2027 in the Cancer Immunotherapy market. The growth in the region can be attributed to growing prevalence of various types of cancer. Increasing technological innovations in Cancer Immunotherapy is also expected to impel the growth of Cancer Immunotherapy market in the North America. U.S. is the prominent market driving the growth in the region.

Additionally, U.S. Cancer Immunotherapy market reached USD 13,392.7 Million in 2017 and is expected to reach USD 27,986.4 Million by the end of 2027, expanding at a CAGR of 7.7% over the forecast period i.e. 2018-2027. U.S. Cancer Immunotherapy market is expected to achieve Y-o-Y growth rate of 8.6% in 2027 as compared to previous year.

Europe market is expected to expand at CAGR of 7.8% during the forecast period i.e. 2018-2027. Europe Cancer Immunotherapy market is projected to reach to a valuation of USD 25,830.2 Millionby the end of 2027 from USD 12,349.4 Million in 2017.

Global Cancer Immunotherapy market is segmented on the basis of technology into Cellular Immunotherapy, Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines & Cytokine Therapy. Among these segments, Monoclonal Antibodies segment (65.5% share in 2017) occupies the largest market of Cancer Immunotherapy across the globe. Further, global Monoclonal Antibodies segment is anticipated to reach USD 56,290.7 Million by the end of 2027 from USD 27,911.8 Million in 2017. Moreover, this segment is anticipated to flourish at a CAGR of 7.4% over the forecast period. In addition, Immune Checkpoint Inhibitors segment of Cancer Immunotherapy is expected to achieve Y-o-Y growth rate of 8.9% in 2027 as compared to previous year.

In addition this, global Cancer Immunotherapy market is also segmented by end-user. In end-user segment, the hospitals segment is estimated to capture the highest market share during the forecast period. This segment contributed around 65.3% market share of total Cancer Immunotherapy market in 2017. Further, this segment is projected to capture 64.2% market share by 2027. Further, hospitals segment is projected to achieve Y-o-Y growth rate of 8.1% in 2027 as compared to previous year.

Pfizer, Merck, Amgen and Roche are some of the prominent players of Cancer Immunotherapy market.

Key Topics Covered:

1. Research Methodology

2. Market Definitions, Assumptions & Abbreviations

3. Market Taxonomy

4. Global Cancer Immunotherapy Market - Executive Summary

4.1. Market Extracts by Technology

4.2. Market Extracts by End User

4.3. Market Extracts by Region

5. Cancer Immunotherapy Product Overview

5.1. Product Timeline

5.2. Features, by Product

5.3. Pipeline Products

6. Top Countries with Highest Demand for Cancer Immunotherapy, 2017

7. Recent Changes and Development in Cancer Immunotherapy Market by Geography

7.1. New Product Development

7.2. Merger and Acquisition

7.3. Expansion and others

8. Regional Average Pricing Analysis, 2017

9. Cancer Immunotherapy Value Chain Analysis

10. Supply Chain Analysis

10.1. Global Trade Agreement and Regulations, By Country

10.2. Global Trade Statistics (Exports and Imports), By Country

11. Porter's Five Force Model Analysis

12. Cancer Immunotherapy Market - Risk Analysis

12.1. Demand Risk Analysis

12.2. Supply Risk Analysis

13. Market Dynamics & Its Impact Analysis

13.1. Growth Drivers

13.2. Challenges

13.3. Trends

13.4. Opportunities

14. Global Cancer Immunotherapy Market Value Forecast (USD Million) & Y-o-Y Growth (%), 2017-2027

15. Global Cancer Immunotherapy Market Segmentation Analysis By Technology

15.1. Introduction

15.2. Cellular Immunotherapy

15.3. Monoclonal Antibodies

15.4. Immune Checkpoint Inhibitors

15.5. Cancer Vaccines

15.6. Cytokine Therapy

15.7. Market Attractiveness Analysis By Technology

15.8. Market Contribution and BPS Analysis, 2017 & 2027 By Technology

16.1. Introduction

16.2. Hospitals

16.3. Ambulatory Surgical Centers (ASCs)

16.4. Clinics

16.5. Others

16.6. Market Attractiveness Analysis By End User

16.7. Market Contribution and BPS Analysis, 2017 & 2027 By End User

17. Global Cancer Immunotherapy Market Segmentation Analysis By Geography

17.1. North America

17.2. Latin America

17.3. Europe

17.4. Asia Pacific

17.5. Middle East & Africa

18. Competitive Landscape

18.1. Competitive Positioning of Major Players in Global Cancer Immunotherapy Market

18.2. Company Profiles

19. Guide to the Industry by Region & Analyst's Recommendations

Companies Mentioned

• AstraZeneca
• Merck
• Novartis
• Advaxis Inc.
• Bristol Myers Squibb
• Bayer
• Roche
• Eli Lily and Co.
• Amgen Inc.
• Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/research/rtxpj9/global_cancer?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager 
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716